
CLAIMS

1. A compound of formula (I),



Formula (I)

wherein,

V is selected from C and N such that the aromatic ring containing V is phenyl or pyridine;

R2 is absent when V is N; or, when present, R2 is selected from H, alkyl, alkoxy, CN, halo and CF_3;

R1 and R3 are independently selected from H, alkyl, alkoxy, CN, halo and CF_3;

W, X, Y and Z are independently selected from C, N, O and S, such that the ring containing W, X, Y and Z is a five-membered aromatic heterocycle;

wherein,

R5, R6 and R7 are independently absent or independently selected from H, alkyl, halo, aryl, heteroaryl and CF_3;

P is $–C(R10)(R11)NH_2$;

R8 and R9 are independently selected from H and alkyl, or may together form a cycloalkyl ring;

R10 and R11 are independently selected from H and alkyl, or may together form a cycloalkyl ring or a cyclic ether;

A is selected from N-linked morpholine, aryl, heteroaryl,

alkyl is a linear saturated hydrocarbon having up to 10 carbon atoms (C_1-C_{10}) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C_3-C_{10}); alkyl may optionally be substituted with 1 or 2 substituents independently selected from (C_1-C_6)alkoxy, OH, CN, CF_3, -COOR12, -CONR12R13, $H(CH_2)_{1-3}CON(R12)(CH_2)_{1-3}$-, fluoro and -NR12R13;

cycloalkyl is a monocyclic saturated hydrocarbon of between 3 and 7 carbon atoms; wherein cycloalkyl may be optionally substituted with a substituent selected from alkyl, alkoxy and NR12R13;

a cyclic ether is a monocyclic saturated hydrocarbon of between 4 and 7 carbon atoms, wherein one of the ring carbons is replaced by an oxygen atom;

alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C_1-C_6) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C_3-C_6); alkoxy may optionally be substituted with 1 or 2 substituents independently selected from aryl, OH, CN, CF_3, -COOR12, -CONR12R13, fluoro and NR12R13;

aryl is phenyl, biphenyl or naphthyl; aryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, -morpholinyl, -piperidinyl, heteroaryl, $aryl^b$, -O-$aryl^b$, -$(CH_2)_{1-3}$-$aryl^b$, -$(CH_2)_{1-3}$-heteroaryl, -COOR12, -CONR12R13, -$(CH_2)_{1-3}$-NR14R15, CF_3 and NR12R13;

$aryl^b$ is phenyl, biphenyl or naphthyl, which may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, -COOR12, -CONR12R13, CF_3 and NR12R13;

heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR12, S and O; heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, aryl, -$(CH_2)_{1-3}$-aryl, $heteroaryl^b$, -COOR12, -CONR12R13, CF_3 and NR12R13;

heteroaryl^b is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR12, S and O; wherein heteroaryl^b may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, aryl, -$(CH_2)_{1-3}$-aryl, -COOR12, -CONR12R13, CF_3 and NR12R13;

R12 and R13 are independently selected from H and alkyl; or R12 and R13 together with the nitrogen to which they are attached form a 4-, 5-, 6- or 7-membered heterocylic ring which may be saturated or unsaturated with 1 or 2 double bonds

R14 and R15 together with the nitrogen to which they are attached form a 4-, 5-, 6- or 7-membered heterocylic ring which may be saturated or unsaturated with 1 or 2 double bonds, and optionally may be oxo substituted;

wherein,

when R5, R6 and R7 are absent or H, then:

either

R10 and R11 together form a cycloalkyl ring or a cyclic ether;

or

A is aryl and aryl is phenyl, biphenyl or naphthyl substituted with 1, 2 or 3 substituents independently selected from OH, heteroaryl, aryl^b, -O-aryl^b, -$(CH_2)_{1-3}$-aryl^b, -$(CH_2)_{1-3}$-heteroaryl, -COOR12, -CONR12R13, and -$(CH_2)_3$-NR14R15; wherein,

aryl^b is phenyl, biphenyl or naphthyl, wherein aryl^b is substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, -COOR12, -CONR12R13, CF_3 and NR12R13; and

heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR12, S and O, wherein heteroaryl is substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, halo, CN, aryl, morpholinyl, piperidinyl, -$(CH_2)_{1-3}$-aryl, heteroaryl^b, -COOR12, -CONR12R13, CF_3 and -NR12R13;

or

A is heteroaryl and heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently

selected from N, NR12, S and O, wherein heteroaryl is substituted with 1, 2 or 3 substituents independently selected from aryl, -$(CH_2)_{1-3}$-aryl, heteroaryl^b, -COOR12, and -CONR12R13;wherein,


aryl is phenyl, biphenyl or naphthyl, wherein aryl is substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, heteroaryl, aryl^b, -O-aryl^b, -$(CH_2)_{1-3}$-aryl^b, -$(CH_2)_{1-3}$-heteroaryl, -COOR12, -CONR12R13, -COR12R13, -$(CH_2)_{1-3}$-NR14R15, CF_3 and -NR12R13; and


heteroaryl^b is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR12, S and O, wherein heteroaryl^b is substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, halo, CN, morpholinyl, piperidinyl, aryl, -$(CH_2)_{1-3}$-aryl, -COOR12, -CONR12R13, CF_3 and NR12R13;


and tautomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), pharmaceutically acceptable salts and solvates thereof.


2. A compound according to claim 1 wherein at least one of R5, R6 and R7 is selected from alkyl, halo, aryl, heteroaryl and CF_3.


3. A compound according to claim 1 or claim 2 wherein A is selected from:







,


,



,


.








, and .

4. A compound of according to any preceding one of claims 1 to 3 wherein A is :

.

5

5. A compound according to claim 1 wherein R5, R6 and R7 are absent or H; and A is selected from:


and .

10 6. A compound according to any one of claims 1 to 4 wherein, X is N and W, Y and Z are C.

7. A compound according to claim 6 wherein, R5 is H, and R6 and R7 are methyl.

15 8. A compound according to any one of claims 1 to 7 wherein R8 and R9 are H.

9. A compound according to any one of claims 1 to 5, wherein:
W is C;

X is N;

Y is C;

Z is C;

R5 is H;

R6 and R7 are CH_3;

R8 and R9 are H; and

R10 and R11 are both H or together form a cyclopropane ring.

10. A compound according to any one of claims 1 to 9 wherein V is C.

11. A compound according to any one of claims 1 to 10 wherein R1 is alkyl and/or R3 is alkyl.

12. A compound according to claim 1 selected from:

2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide;

2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;

2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;

2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-(1-amino-cyclopropyl)-benzylamide;

2,5-Dimethyl-1-(6-phenyl-pyridin-2-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide;

1-[2-(3-Fluoro-phenyl)-thiazol-4-ylmethyl]-2,5-dimethyl-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide;

2,5-Dimethyl-1-(2-thiophen-3-yl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide;

2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid (6-aminomethyl-pyridin-3-ylmethyl)-amide;

2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-3-fluoro-benzylamide;

2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-fluoro-benzylamide;

2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-chloro-benzylamide;

2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-trifluoromethyl-benzylamide;

2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methoxy-benzylamide;

1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid 4-aminomethyl-benzylamide;

1-[4-(3,5-Dimethyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid 4-aminomethyl-benzylamide;

2,5-Dimethyl-1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide;

2,5-Dimethyl-1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;

1-Ethyl-4-methyl-5-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;

2,5-Dimethyl-1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;

1-Ethyl-4-methyl-5-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;

2,5-Dimethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide;

2,5-Dimethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;

1-Ethyl-4-methyl-5-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;

2,5-Dimethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;

1-Ethyl-4-methyl-5-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;

1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-imidazole-4-carboxylic acid 4-aminomethyl-benzylamide;

1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;

1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-imidazole-4-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;

1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-[1,2,3]triazole-4-carboxylic acid 4-aminomethyl-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-[1,2,3]triazole-4-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-imidazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-[1,2,3]triazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-Ethyl-4-methyl-5-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-benzylamide;
1-Ethyl-4-methyl-5-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-benzylamide;
5-Methyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-aminomethyl-3-fluoro-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-aminomethyl-3-fluoro-2-methyl-benzylamide;
3-Methyl-1-(2-methyl-quinolin-6-ylmethyl)-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
5-Methyl-1-(2-methyl-quinolin-6-ylmethyl)-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-(2-Methyl-quinolin-6-ylmethyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-(2-Pyrrolidin-1-yl-pyridin-4-ylmethyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
and pharmaceutically acceptable salts and solvates thereof.

13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12 and a pharmaceutically acceptable carrier, diluent or excipient.

14. A compound according to any one of claims 1 to 12 for use in medicine.

15. A compound according to any one of claims 1 to 12 for use in a method of treatment of a disease or condition in which plasma kallikrein activity is implicated selected from impaired visual acuity, diabetic retinopathy, diabetic macular edema, hereditary angioedema, diabetes, pancreatitis, cerebral haemorrhage, nephropathy, cardiomyopathy, neuropathy, inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, cardiopulmonary bypass surgery and bleeding from post operative surgery.

16. A compound for use as claimed in claim 15, wherein the disease or condition in which plasma kallikrein activity is implicated is retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.